Preliminary Clinical Study on the Effect of L-ornithine on the Efficacy of Ustekinumab in Patients With Crohn's Disease

This study investigates whether L-ornithine — an amino acid supplement — can improve the effectiveness of ustekinumab (a biologic drug that suppresses inflammation) in patients with Crohn's disease, a chronic inflammatory bowel condition. Researchers think L-ornithine may enhance how the immune system responds to the treatment. **You may be eligible if...** - You are aged 18–75 and have been clinically diagnosed with Crohn's disease - You are currently receiving ustekinumab as your treatment - You are willing to participate and sign a consent form **You may NOT be eligible if...** - You have significantly elevated liver enzymes or bilirubin (liver function abnormalities) - You have poor kidney function (creatinine clearance below 60 mL/min) - You have active severe intestinal infections or intestinal tuberculosis - You are pregnant or breastfeeding - You have poorly controlled diabetes (blood sugar or HbA1c above threshold) - You participated in another clinical trial within the past month Talk to your doctor to see if this trial is right for you.